Future of IGA Nephropathy Care: What Patients Should Expect
Understanding IGA Nephropathy and Its Challenges
IGA nephropathy, also known as Berger’s disease, is a chronic kidney condition marked by the buildup of the immunoglobulin A (IgA) antibody in the kidneys. This deposition causes inflammation and damages the glomeruli, impairing the kidneys' ability to filter waste. It often progresses slowly but can eventually lead to end-stage kidney disease in severe cases. With no universal cure, treatment focuses on slowing disease progression and managing symptoms like high blood pressure and proteinuria.
Evolving Treatment Approaches
Current strategies for managing [IGA nephropathy](https://www.marketresearchfuture.com/reports/iga-nephropathy-treatment-market-24490
) range from lifestyle modifications and supportive care to targeted pharmaceutical interventions. The standard approach includes controlling blood pressure using ACE inhibitors or angiotensin receptor blockers (ARBs). Corticosteroids and immunosuppressive therapy are often employed in cases showing rapid disease progression. Additionally, SGLT2 inhibitors, initially used in diabetes management, are now gaining interest in protecting kidney function in IgA nephropathy patients.
Pipeline…